Poolbeg Pharma (LON:POLB) Trading Up 10.1% – Here’s What Happened

Poolbeg Pharma PLC (LON:POLB) shares were up 10.1% on Wednesday . The stock traded as high as GBX 5.84 and last traded at GBX 5.55. Approximately 5,824,547 shares were traded during mid-day trading, an increase of 359% from the average daily volume of 1,268,309 shares. The stock had previously closed at GBX 5.04.

Analyst Upgrades and Downgrades

Separately, Shore Capital Group reissued a “house stock” rating on shares of Poolbeg Pharma in a research report on Tuesday.

Poolbeg Pharma Stock Up 2.5%

The company has a market capitalization of £40.47 million, a P/E ratio of -6.11 and a beta of 1.78. The firm has a 50-day moving average price of GBX 4.52 and a two-hundred day moving average price of GBX 4.32.

Poolbeg Pharma (LON:POLB) last posted its quarterly earnings data on Tuesday, April 28th. The company reported GBX (0.94) earnings per share for the quarter. On average, analysts predict that Poolbeg Pharma PLC will post -0.68 EPS for the current fiscal year.

Poolbeg Pharma Company Profile

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.